UPDATE 2-Roche cancer treatment priced at $17,050 a month, lower than rival Vitrakvi
Roche Holding AG has priced its personalized cancer treatment, Rozlytrek, at about $17,050 per month, nearly half of the monthly price of a rival drug from Bayer AG and Eli Lilly and Co that was approved last year. [Source]
Publication Date:Origin: reuters.com
Category: companyNews
Topics: rival, priced, treatment, cancer, was approved, Lilly, from Bayer, price, monthly, nearly, per month, Rozlytrek, its personalized, Holding, Roche, Vitrakvi, lower, month, 2-Roche, UPDATE